तुलना करने के लिए मीट्रिक्स | 203400 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध203400पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −8.5x | −16.3x | −0.5x | |
PEG अनुपात | −0.17 | −0.28 | 0.00 | |
क़ीमत/बुक | 3.6x | 3.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 280.5x | 26.6x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 258.3% | 48.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | −1.8% | 6.9% | अनलॉक करें |
ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various respiratory viruses. It is also developing ABN701 for SEBI infectious diseases; and ABN 901, ABN 902, and ABN 903 for infectious diseases related to biological disasters. Abion Inc. was founded in 2007 and is based in Seoul, South Korea.